萘哌地尔治疗女性尿道综合征初探

目的:分析萘哌地尔治疗女性尿道综合征的有效性。方法:35例患者采用自身对照试验,应用萘哌地尔片25mg,每晚口服。以自由尿流率的主要参数如最大尿流率(MFR)、平均尿流率(AFR)、排尿量(VV)和尿道综合征症状评分(FUSS)、生活质量评分(QOL)为疗效指标观察治疗效果。结果:治疗2周后患者症状好转或消失。治疗前后的MFR、AFR、VV、FUSS、QOL相比较,显示出差异有统计学意义(P<0.01),总有效率为82.86%。结论:萘哌地尔治疗女性尿道综合征有效、安全,值得临床试用。

The efficacy of naftopidil in treatment of female urethral syndrome

Objective:To evaluate the efficacy and safety of naftopidil in treatment of female patients with urethral syndrome (FUS). Methods:Self-controlled clinical trial was performed in patients with FUS. Thirty-five patients were treated with naftopidil tablet 25mg ,po, qn for 2 weeks after one-week washout period. The effects were evaluated mainly by urodynamic data including maximum flow rate(MFR), average flow rate(AFR), voiding volume(VV), female urethral syndrome score (FUSS) and quality of life (QOL). Results:Urodynamic data(MFR,AFR,VV)increased while FUSS decreased significantly after 2 weeks′treatment. There was statistical difference in urodynamics data, FUSS and QOL between before and after treatment (P<0.01 ). The total effective rate was 82.86%. Conclusion: Naftopidil tablet was safe and effective in treating FUS.